Editas Medicine, Inc. (NASDAQ:EDIT)‘s stock had its “equal weight” rating reaffirmed by stock analysts at Morgan Stanley in a report issued on Friday. They currently have a $28.00 price target on the stock, up from their previous price target of $27.00. Morgan Stanley’s price target points to a potential upside of 11.96% from the company’s current price.

EDIT has been the subject of several other reports. Zacks Investment Research raised Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Wednesday, July 12th. Cann started coverage on Editas Medicine in a research report on Monday, July 17th. They set a “market perform” rating for the company. J P Morgan Chase & Co set a $27.00 price objective on Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. ValuEngine raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, SunTrust Banks, Inc. started coverage on Editas Medicine in a research report on Thursday, July 13th. They set a “hold” rating and a $17.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $25.88.

Shares of Editas Medicine (NASDAQ:EDIT) opened at 25.01 on Friday. Editas Medicine has a 52 week low of $12.43 and a 52 week high of $28.50. The stock’s market capitalization is $1.02 billion. The company has a 50-day moving average price of $22.35 and a 200 day moving average price of $22.35.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The firm’s quarterly revenue was down 8.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.54) earnings per share. Analysts forecast that Editas Medicine will post ($2.88) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/editas-medicine-inc-edit-stock-rating-reaffirmed-by-morgan-stanley/1617265.html.

In other news, insider Katrine Bosley sold 16,666 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $20.33, for a total transaction of $338,819.78. Following the completion of the transaction, the insider now directly owns 1,414,629 shares of the company’s stock, valued at $28,759,407.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 51,665 shares of company stock valued at $1,083,165 over the last ninety days. 19.40% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paulson & CO. Inc. bought a new stake in Editas Medicine during the first quarter worth about $1,116,000. UBS Group AG raised its holdings in Editas Medicine by 747.7% during the first quarter. UBS Group AG now owns 78,217 shares of the company’s stock worth $1,746,000 after acquiring an additional 68,990 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in Editas Medicine by 169.8% during the first quarter. Driehaus Capital Management LLC now owns 125,684 shares of the company’s stock worth $2,805,000 after acquiring an additional 79,104 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in Editas Medicine during the second quarter worth about $1,322,000. Finally, Omega Advisors Inc. bought a new stake in Editas Medicine during the first quarter worth about $1,116,000. Institutional investors and hedge funds own 69.37% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.